Protagonist Therapeutics, Inc. PTGX 深 滬
交易中 09-05 10:10:09 美东时间
59.665
+0.065
+0.11%
華盛通- 最 高60.12
- 今 開59.34
- 成交量 19.17万股
- 最 低 59.10
- 昨 收 59.60
- 總市值 36.98亿
- 52周最高 61.89
- 市盈率 靜 14.11
- 換手率 0.31%
- 52周最低 33.31
- 委 比 -59.18%
- 總股本 6198.20万
- 歷史最高 61.89
- 量 比 3.02
- 振 幅 1.71%
- 歷史最低 4.47
- 每 手 1
- 風險率 6.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Protagonist Plans Year-End FDA Filing for Rusfertide After Strong Phase 3 Results in Blood Disorder Therapy
Protagonist Therapeutics, Inc. ("Protagonist" or "the Company") announced today that rusfertide, a potential first-in-class hepcidin-mimetic peptide, has been granted Breakthrough Therapy Designation by the U.S. Food and
08-25 19:09
What 4 Analyst Ratings Have To Say About Protagonist Therapeutics
In the preceding three months, 4 analysts have released ratings for Protagonist...
08-08 02:01
JMP Securities Maintains Market Outperform on Protagonist Therapeutics, Raises Price Target to $69
JMP Securities analyst Jonathan Wolleben maintains Protagonist Therapeutics (NASDAQ:PTGX) with a Market Outperform and raises the price target from $67 to $69.
08-07 21:37
Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates
Protagenic Therapeutics received a patent (JP 7714571B) in Japan for a modified stilbenoid to treat epilepsy and seizures. The patent, granted on July 18, 2025, provides exclusivity until March 2041. Colin Stott highlighted the importance of this patent, following its previous grant in the UK, and plans to expand its coverage in other territories. Japan's pharmaceutical market is the world's third largest, valued at over $85 billion in 2025 and e...
07-30 12:30
口服多肽向FDA递交上市申请 药明康德共同强生等参与
据药明康德（603259.SH）官微7月22日消息，药明康德共同强生（Johnson & Johnson）与Protagonist Therapeut...
07-22 09:22
Protagonist Therapeutics And Johnson & Johnson Submit NDA For Icotrokinra, A First-in-Class Oral IL-23 Receptor Blocker, Following Phase 3 Results In Plaque Psoriasis
Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptorFiling based on unprecedented data package that met all primary endpoints across four Phase 3 studies,
07-21 20:06
新浪财经ESG：PTGX MSCI（明晟）ESG评级调降至BB
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务，助力上市公司传播ESG理念，提升ESG可持续发展表现。点击查看【 ESG评级中...
06-28 07:00
Protagonist Therapeutics to Reveal Oral Obesity Drug Development Candidate and Study Results in Upcoming Call
Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its oral obesity development candidate and to share in vitro and
06-26 19:09
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
06-18 09:46
Citigroup Initiates Coverage On Protagonist Therapeutics with Buy Rating, Announces Price Target of $72
Citigroup analyst Geoff Meacham initiates coverage on Protagonist Therapeutics (NASDAQ:PTGX) with a Buy rating and announces Price Target of $72.
06-17 19:44
